Search for a trial

A clinical imaging Study of the changes in [18F]F-AraG uptake following radiotherapy in Non-small cell lung cancer.

This study has been transitioned to CTIS with ID 2024-517960-45-00 check the CTIS register for the current data. • To assess the relative change in uptake of [18F]F-AraG in tumor lesions upon anti-PD-1 treatment• To assess the relationships between…

Preparation of AKT-DC from Lymph nodes derived through Surgery and Endobronchial ultrasound guided biopsy in non-small cell lung cancer patients.

To assess whether procedures and techniques used to derive AKT-DC out of lymph node material influences the quality and number of the AKT-DC end-product.

Injection of 99mTc-nanocolloid and ICG to identify, retrieve and qualify tumor draining lymph nodes in early-stage lungcancer

The primary objective is to determine the feasibility of identifying the TDLN in patients with NSCLC (cT1 to cT2b) on SPECT/CT imaging and during surgical resection using a radioactive and fluorescent tracer, 99mTc-nanocolloïd and ICG respectively.…

A Multicenter, Phase 1/1b Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors

The purpose of this study is to evaluate how safe telisotuzumab vedotin is and how telisotuzumab vedotin is tolerated as monotherapy and in combination with osimertinib.

A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined with Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC)

Sub-study APhase 1b:To assess the DLT rate and estimate the MTD of sasanlimab in combination with encorafenib and binimetinib to determine the RP2D for the combination. Phase 2:To assess the durable ORR of sasanlimab in combination with encorafenib…

Response and Toxicity Prediction by Microbiome analysis in locally advanced NSCLC treated with IO (durvalumab) after Chemoradiotherapy (sequential and concurrent)

The predictive value of the microbiome (throat swabs and stool samples) to identify patients who will relapse during durvalumab treatment after CRT (False negative Rate) at 6 months. Exploratory endpoints include the effects of antibiotic therapy…

Characterizing tissue protein synthesis rates of non-small cell lung carcinomas in lung cancer patients

The current study aims to recruit a greater number of lung cancer patients to measure tissue protein synthesis rates of non-small cell lung carcinomas and healthy lung tissue. The protein synthesis rates of healthy lung tissue will be compared to…

MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL
ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS

Primary: The primary objective of this study is to determine the biomarker status of patients screened in this master screening study and their potential biomarker eligibility to participate in a linked Roche clinical trial.Exploratory:The…

Prospective primary human lung cancer tumoroids to predict treatment response

To establish matched normal and primary human lung cancer organoids from patient-derived lung (tumor) material.

The effect of extra hydration on kidney function during carboplatin-pemetrexed-pembrolizumab in patients with advanced non-small cell lung cancer.;*Hydration to prevent nephrotoxicity due to pemetrexed (HydraPem Study)*

To investigate the effect of fluid infusion to prevent deterioration of kidney function due to pemetrexed, during treatment with carboplatin, pemetrexed and pembrolizumab in patients with non-squamous NSCLC. The primary objective is to reduce the…

Standard dose alectinib versus Therapeutic Drug Monitoring guided alectinib dosing

This study has been transitioned to CTIS with ID 2023-506886-76-00 check the CTIS register for the current data. The primary objective will be a prolonged mPFS for the TDM-guided dosing cohort versus the standard fixed dosing cohort in the group of…

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations

This study has been transitioned to CTIS with ID 2023-508349-42-00 check the CTIS register for the current data. Stage 1 Primary ObjectiveTo evaluate the safety and tolerability, determine the expansion dose, and characterize dose-limiting…

A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY

This study has been transitioned to CTIS with ID 2023-509429-37-00 check the CTIS register for the current data. In this study, we want to learn more about the effect and safety of Ceralasertib plus Durvalumab on the inhibition of tumour growth, and…

A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer

This study has been transitioned to CTIS with ID 2023-503517-30-00 check the CTIS register for the current data. Primary objectivesTo compare overall survival for MK-7684A in combination with the background therapy of etoposide/platinum followed by…

KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression >= 1% and an STK11 co-mutation.

This study has been transitioned to CTIS with ID 2024-511708-18-00 check the CTIS register for the current data. the Sponsor aims to investigate if JDQ443 will stop abnormal cell growth related to the marker KRAS G12C mutation in patients with NSCLC…

A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

This study has been transitioned to CTIS with ID 2023-505749-14-00 check the CTIS register for the current data. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab…

A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations

This study has been transitioned to CTIS with ID 2023-509825-38-00 check the CTIS register for the current data. To compare the effect of ZIM and DOM in combination with chemotherapy relative to PEMBRO in combination with chemotherapy (Group A…

A PHASE I-III, MULTICENTER STUDY
EVALUATING THE EFFICACY AND SAFETY OF
MULTIPLE THERAPIES IN COHORTS OF
PATIENTS SELECTED ACCORDING TO
BIOMARKER STATUS, WITH LOCALLY
ADVANCED, UNRESECTABLE, STAGE III
NON-SMALL CELL LUNG CANCER

This study has been transitioned to CTIS with ID 2023-503920-14-00 check the CTIS register for the current data. The overall objectives of this study are to evaluate the efficacy and safety of multiple therapies in patients with locally advanced,…